Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Current Investments: 2016-2024

Historic Cash & Current Investments for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $236.7 million.

  • UroGen Pharma's Cash & Current Investments fell 49.10% to $127.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $716.6 million, marking a year-over-year decrease of 9.49%. This contributed to the annual value of $236.7 million for FY2024, which is 72.80% up from last year.
  • Per UroGen Pharma's latest filing, its Cash & Current Investments stood at $236.7 million for FY2024, which was up 72.80% from $137.0 million recorded in FY2023.
  • UroGen Pharma's Cash & Current Investments' 5-year high stood at $236.7 million during FY2024, with a 5-year trough of $89.1 million in FY2021.
  • Over the past 3 years, UroGen Pharma's median Cash & Current Investments value was $137.0 million (recorded in 2023), while the average stood at $157.9 million.
  • In the last 5 years, UroGen Pharma's Cash & Current Investments slumped by 30.64% in 2020 and then soared by 72.80% in 2024.
  • UroGen Pharma's Cash & Current Investments (Yearly) stood at $102.0 million in 2020, then declined by 12.62% to $89.1 million in 2021, then climbed by 12.14% to $100.0 million in 2022, then surged by 37.02% to $137.0 million in 2023, then soared by 72.80% to $236.7 million in 2024.